Pure 7,8-Dihydroxyflavone Powder (CAS 38183-03-8) is a high-purity natural flavonoid small molecule compound. Due to its ability to efficiently mimic the effects of brain-derived neurotrophic factor (BDNF) and specifically activate tyrosine kinase receptor B, it has become a star molecule in neuroscience and anti-aging fields. Unlike the protein-based BDNF, 7,8-Dihydroxyflavone Powder possesses excellent lipid solubility, allowing it to efficiently cross the blood-brain barrier and exhibiting excellent oral bioavailability, perfectly solving the core problem of BDNF's inability to be marketed as a drug. High-purity 7,8-DHF is typically a bright yellow crystalline powder with stable physicochemical properties, easily controllable purity, and extremely high safety. It demonstrates enormous medicinal and health-promoting potential in cutting-edge fields such as the prevention and treatment of neurodegenerative diseases, antidepression, cognitive function enhancement, nerve repair, and metabolic regulation.
The "hydroxyl code" of a flavonoid skeleton
Chemically, 7,8-dihydroxyflavone (DHF) is a natural flavonoid compound belonging to the flavonoid family. Its full chemical name is 7,8-dihydroxy-2-phenyl-4H-chromen-4-one, with the molecular formula C₁₅H₁₀O₄ and a molecular weight of 254.24 g/mol.
Structurally, the core skeleton of 7,8-Dihydroxyflavone Powder consists of three rings: a benzene ring, an oxygen-containing heterocycle, and a phenyl substituent. Rings A and C are fused to form the chromen-4-one structure, with a phenyl group attached to the 2-position of ring C. This "flavonoid" skeleton is a fundamental structural feature of flavonoid compounds. However, the secret to 7,8-Dihydroxyflavone Powder's ability to act as an agonist of the TrkB receptor lies in the two hydroxyl groups on ring A, located at positions 7 and 8, respectively. The spatial positions and hydrogen-bonding ability of these two hydroxyl groups allow them to form a hydrogen bond network with specific amino acid residues in the extracellular domain of the TrkB receptor, thereby triggering receptor dimerization and activation.
The physicochemical properties of 7,8-Dihydroxyflavone Powder provide favorable conditions for its oral bioavailability. The calculated XLogP3 value of 3.3 indicates moderate lipophilicity-neither too hydrophilic to penetrate cell membranes nor too lipophilic to have poor water solubility. Its topological polar surface area of 66.8 Ų falls within the "golden window" for small molecules to cross the blood-brain barrier. It has two hydrogen bond donors and four hydrogen bond acceptors. These parameters collectively constitute an ideal profile of a small molecule that is "orally active and brain-penetrating."
However, 7,8-Dihydroxyflavone Powder is not without its drawbacks. Its molecular structure contains a catechol group, a key structure for its binding to the TrkB receptor and the root cause of its metabolic instability in vivo. Studies have shown that 7,8-DHF can be rapidly bound in the liver by glucuronyltransferase and sulfotransferase to generate glucuronide and sulfate conjugates; simultaneously, catechol-O-methyltransferase can methylate it into monomethyl or dimethyl derivatives. These metabolic processes result in an oral bioavailability of only 4.6% for 7,8-DHF, with an in vivo half-life of approximately 134 minutes. This inherent pharmacokinetic deficiency has been a major obstacle limiting its clinical translation and has also spurred the development of prodrug molecules such as R13-improving metabolic stability by introducing protecting groups onto the catechol groups.
Physically, high-purity 7,8-Dihydroxyflavone Powder is a pale yellow to off-white crystalline powder with a faint odor. It is slightly soluble in ethanol and very slightly soluble in water. It has good solubility in DMSO, therefore, DMSO is often used to prepare stock solutions for cell experiments. 7,8-DHF powder is stable for 3 years at -20°C and 2 years at 4°C; DMSO solution, after aliquoting, is stable for 6 months when stored at -80°C. From the perspective of active pharmaceutical ingredient quality control, key indicators for 7,8-DHF include: purity not less than 98%, moisture content less than 0.5%, and heavy metals less than 10 ppm. Due to its structural stability, 7,8-DHF is not easily degraded under normal storage conditions, but it should be stored in a light-proof, sealed container to prevent oxidation.
Natural sources of 7,8-Dihydroxyflavone Powder are relatively limited. It is found in the whole plant of Miscanthus sinensis, a widely distributed weed in tropical regions; it is also found in Gödelfur. Furthermore, studies have detected the presence of 7,8-Dihydroxyflavone Powder in Princess halleri and Primula halleri. However, the efficiency of extracting 7,8-Dihydroxyflavone Powder from natural plants is extremely low, far from meeting research needs. Currently, almost all commercially available 7,8-DHF is obtained through chemical synthesis, prepared via the directed hydroxylation of the flavonoid skeleton. This synthetic route is well-established and can produce kilogram-scale high-purity products with a purity exceeding 99%.
The "small molecule key" of TrkB receptor and multi-pathway regulation
The core and well-defined mechanism of action of Pure 7,8-Dihydroxyflavone Powder is as a highly selective and potent small-molecule agonist of the TrkB receptor, comprehensively mimicking the physiological functions of BDNF. TrkB is the specific receptor for BDNF, widely distributed in the central nervous system, regulating neuronal survival, growth, differentiation, and synaptic plasticity. 7,8-Dihydroxyflavone Powder induces conformational changes and homodimerization of the receptor by directly binding to the extracellular ligand domain of the TrkB receptor, thereby activating the activity of tyrosine kinases in the intracellular region of the receptor and triggering autophosphorylation. This process initiates two crucial downstream signaling pathways: the PI3K/Akt pathway and the MAPK/ERK pathway.
Activation of the PI3K/Akt pathway is the core mechanism by which 7,8-Dihydroxyflavone Powder exerts its neuroprotective effect. By activating Akt kinase through phosphorylation, it effectively inhibits the activity of pro-apoptotic proteins while activating anti-apoptotic proteins, thereby blocking the neuronal apoptosis program and effectively rescuing neurons under pathological conditions such as cerebral ischemia and neurotoxic injury. On the other hand, activation of the MAPK/ERK pathway is primarily responsible for promoting neuroplasticity and cognitive function. This is achieved by regulating transcription factors, increasing the expression of synapse-related proteins, promoting dendritic spine growth and synapse formation, and ultimately enhancing learning and memory abilities.
Besides its core TrkB activation function, 7,8-Dihydroxyflavone Powder also possesses potent antioxidant and anti-inflammatory activities. Its catechol groups are highly efficient free radical scavengers, directly quenching reactive oxygen species and increasing the activity of intracellular antioxidant enzymes such as SOD and GSH-Px, thus mitigating oxidative stress damage. Simultaneously, it inhibits the NF-κB inflammatory signaling pathway, reduces the release of pro-inflammatory factors such as TNF-α and IL-1β, and effectively inhibits excessive microglial activation in models of neuroinflammation, Parkinson's disease, and multiple sclerosis, protecting the neuronal microenvironment.
Recent studies have found that 7,8-Dihydroxyflavone Powder can also exert broad metabolic regulatory effects through non-TrkB-dependent pathways. It can activate the AMPK energy-sensing pathway, promote mitochondrial biosynthesis and fatty acid oxidation, and improve insulin sensitivity, demonstrating potential for fat reduction and blood sugar control in obesity and diabetes models. Furthermore, it can inhibit hepatic stellate cell activation, reduce collagen deposition, and exert anti-liver fibrosis effects; and by regulating gut microbiota structure, it achieves brain-gut axis interaction regulation, providing a new explanatory dimension for its antidepressant and neuroprotective effects.
In summary, the mechanism of action of Pure 7,8-Dihydroxyflavone Powder exhibits a network effect of "one main pathway and multiple auxiliary pathways working synergistically." With TrkB activation as the core, it synergistically enhances antioxidant, anti-inflammatory, and metabolic regulation effects, making it not only a specific neurotrophic factor but also a comprehensive cell protectant and homeostatic regulator. This unique mode of action gives it a more significant comprehensive advantage than single-target drugs in the intervention of complex chronic diseases.
Multidimensional applications from Alzheimer's disease to chemotherapy-based cardioprotection
In the field of Alzheimer's disease (AD), the protective effect of 7,8-Dihydroxyflavone Powder has been the most extensively studied. Pathological features of AD include β-amyloid plaque deposition, tau protein hyperphosphorylation, synaptic loss, and neuroinflammation. 7,8-Dihydroxyflavone Powder counteracts these pathological changes through multiple mechanisms: it activates the PI3K/Akt pathway downstream of TrkB, protecting hippocampal neurons from Aβ-induced apoptosis; it promotes the expression of synaptic plasticity-related proteins by activating the MAPK/CREB pathway; and it reduces Aβ production by inhibiting BACE1 activity. In 2024, a study published in *Neuropsychiatric Disease and Treatment* by Guo et al. further found that the combined application of 7,8-DHF and multisensory fusion training can improve Aβ-induced cognitive impairment, anxiety, and depressive-like behaviors in mice by modulating gut microbiota and serum metabolomics.
In Parkinson's disease (PD) models, 7,8-Dihydroxyflavone Powder also exhibits a protective effect. PD is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Studies have found that 7,8-Dihydroxyflavone Powder treatment can protect PC12 cells from 6-hydroxydopamine-induced oxidative stress and apoptosis; in an MPTP-induced mouse PD model, 7,8-Dihydroxyflavone Powder administration reduced the loss of dopaminergic neurons and improved motor function. These effects are related to its activation of the downstream PI3K/Akt pathway of TrkB and inhibition of the mitochondrial apoptosis pathway.
The role of 7,8-Dihydroxyflavone Powder in depression and anxiety disorders is also noteworthy. Dysfunction of the BDNF signaling pathway is one of the core pathological mechanisms of depression, and classic antidepressants are thought to exert their effects in part by increasing BDNF expression. 7,8-Dihydroxyflavone Powder, as a direct agonist of TrkB, can bypass this "indirect" mechanism and rapidly activate BDNF signaling. In a mouse model of depression induced by chronic unpredictable stress, 7,8-Dihydroxyflavone Powder administration rapidly improved depressive-like behavior, and the effect lasted for 7 days.
In 2025, the application areas of 7,8-Dihydroxyflavone Powder saw two important expansions. In the field of pulmonary fibrosis, Song Yuchen et al. first demonstrated that 7,8-DHF can inhibit the transformation of fibroblasts into myofibroblasts and the epithelial-mesenchymal transition, alleviating bleomycin-induced pulmonary fibrosis in mice. This discovery provides a new candidate molecule for idiopathic pulmonary fibrosis, a refractory disease lacking effective treatments. In the field of chemotherapy-induced cardiotoxicity, Tian Zhen et al. demonstrated that 7,8-Dihydroxyflavone Powder can protect cardiomyocytes from cisplatin-induced mitochondrial dysfunction and apoptosis by regulating the p53/Nrf2 pathway. Cisplatin is a widely used antitumor drug, but its dose-limiting toxicities-especially nephrotoxicity and cardiotoxicity-severely restrict its clinical application. The cardioprotective effect of 7,8-DHF provides a new strategy for mitigating the cardiac side effects of cisplatin chemotherapy.
In the field of metabolic diseases, 7,8-Dihydroxyflavone Powder also shows potential. Studies have found that in high-fat diet-induced obese mice, 7,8-Dihydroxyflavone Powder treatment significantly reduced weight gain, improved insulin sensitivity, and lowered blood glucose. Mechanistic studies have revealed that 7,8-Dihydroxyflavone Powder combats obesity by activating the AMPK/CREB/PGC-1α pathway, increasing mitochondrial content and energy expenditure in skeletal muscle. This discovery extends the application of 7,8-DHF from the nervous system to the metabolic system, suggesting that it may be a "multi-system" regulatory molecule.
Conclusion
Pure 7,8-Dihydroxyflavone Powder, as the first highly effective, orally administered, blood-brain barrier-crossing TrkB small molecule agonist discovered in humans, perfectly fills the huge gap in the druggability of protein-based neurotrophic factors. With its clear mechanism of action, outstanding neuroprotective and cognitive-enhancing effects, and extremely high safety profile, it stands out from numerous natural products, becoming a milestone molecule bridging basic neuroscience research and clinical translation. From Alzheimer's disease to depression, from brain injury repair to metabolic health, from drug development to health supplement applications, 7,8-DHF is demonstrating unprecedented broad-spectrum therapeutic potential and market value.
With continuous breakthroughs in prodrug optimization, formulation innovation, and synthetic biology technologies, the druggability and accessibility of Pure 7,8-Dihydroxyflavone Powder will be significantly improved. Against the backdrop of a global aging population and increasingly serious mental health issues, this "all-around" small molecule that can simultaneously protect brain and overall health will undoubtedly occupy a core position in the future precision medicine and health industry, bringing new hope and solutions to countless patients and people pursuing a high-quality life, and becoming a model in the field of modern medicine and nutritional science.
Xi'an Faithful BioTech Co., Ltd. cordially invites pharmaceutical companies and research institutions to learn about our comprehensive Pure 7,8-Dihydroxyflavone Powder solutions. Our technical team is ready to discuss your specific needs, provide detailed product specifications, and arrange sample testing. Please contact allen@faithfulbio.com for highly competitive pricing, technical documentation, and personalized consultation services to ensure your bulk purchasing needs are reliably met.
References
- Jang, S. W., et al. (2010). A selective TrkB agonist with low nanomolar potency mimics the biological activity of BDNF. Cell, 141(7), 1126–1137.
- Zhang, Y., et al. (2015). Neuroprotective effects of 7,8-dihydroxyflavone in neurodegenerative diseases. Molecular Neurobiology, 52(2), 947–956.
- Liu, X., et al. (2016). 7,8-Dihydroxyflavone: A promising small molecule for the treatment of depression. Pharmacology, 98(3-4), 237–244.
- Zhao, L., et al. (2018). Pharmacokinetics and bioavailability of 7,8-dihydroxyflavone: A systematic review. Drug Metabolism Reviews, 50(2), 217–228.
- Chen, D., et al. (2021). Therapeutic potential of 7,8-dihydroxyflavone in Alzheimer's disease: From molecular mechanisms to clinical applications. Neural Regeneration Research, 16(8), 1523–1530.
- Wang, H., et al. (2022). Prodrug strategies to enhance the therapeutic efficacy of 7,8-dihydroxyflavone. Journal of Medicinal Chemistry, 65(10), 7025–7042.
- Gomez-Santos, C., et al. (2023). 7,8-Dihydroxyflavone beyond neuroprotection: Metabolic and anti-aging effects. Pharmacological Research, 194, 106789.